SEARCH

SEARCH BY CITATION

References

  • 1
    First MR, Fitzsimmons WE. New drugs to improve transplant outcomes. Transplantation 2004; 77: S88-S92.
  • 2
    Vanrenterghem Y, Van Hooff JP, Squifflet JP et al. for the European Tacrolimus/MMF Renal Transplantation Study Group. Minimization of immunosuppressive therapy after renal transplantation: Results of a randomized, controlled trial. Am J Transplant 2005; 5: 8795.
  • 3
    Sabers CJ, Martin MM, Brunn GJ et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270: 815822.
  • 4
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus). Mechanism of action immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335340.
  • 5
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376377.
  • 6
    Hartwig T, Pridoehl O, Witzigmann H et al. Low-dose sirolimus and tacrolimus in kidney transplantation: First results of a single-center experience. Transplant Proc 2001; 33: 32263228.
  • 7
    Van Hooff JP, Squifflet JP, Wlodarczyk Z, Vanrenterghem Y, Paczek L. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 19341939.
  • 8
    El-Sabrout R, Delaney V, Qadir M, Butt F, Hanson P, Butt KMH. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients—a single center experience. Transplant Proc 2003; 35: S89-S94.
  • 9
    Miller J, Burke GW, Ciancio G et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection (abstract 1222). Am J Transplant 2003; 3(Suppl 5): 465.
  • 10
    Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation 2002; 3: 775782.
  • 11
    Gonwa T, Mendez R, Yang HC, Weinstein S, Jensik S, Steinberg S for the Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 2003; 75: 12131220.
  • 12
    Solez K, Benediktsson H, Cavallo T et al. Report of the third Banff conference on allograft pathology (July 20–24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996; 28: 441444.
  • 13
    Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 14
    Maria Grinyo J, Maria Campistol J, Paul J et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 13081314.
  • 15
    Kahan BD for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study. Lancet 2000; 356: 194202.
  • 16
    MacDonald AS for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 1: 271280.
  • 17
    Mendez R, Gonwa T, Yang HC, Weinstein S, Jensik S, Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation. Results at 1 year. Transplantation 2005; 80: 303309.
  • 18
    Steinmueller TM, Graef KJ, Schleicher J et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism: A randomized trial. Transplantation 1994; 58: 669674.
  • 19
    Starzl TE, Fung J, Jordan M et al. Kidney transplantation under FK506. JAMA 1990; 264: 6367.
  • 20
    Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 74: 804808.
  • 21
    Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005; 28: 153181.